ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report)’s share price crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $82.23 and traded as low as $80.90. ProShares Ultra Nasdaq Biotechnology shares last traded at $81.46, with a volume of 5,071 shares.
ProShares Ultra Nasdaq Biotechnology Stock Performance
The firm has a market cap of $75.76 million, a PE ratio of 20.68 and a beta of 1.25. The firm’s 50-day moving average price is $82.23 and its two-hundred day moving average price is $82.24.
Institutional Trading of ProShares Ultra Nasdaq Biotechnology
Institutional investors and hedge funds have recently bought and sold shares of the business. Franklin Resources Inc. acquired a new position in ProShares Ultra Nasdaq Biotechnology in the 2nd quarter valued at $32,000. Citadel Advisors LLC purchased a new position in shares of ProShares Ultra Nasdaq Biotechnology during the 3rd quarter worth about $307,000. Kaizen Financial Strategies acquired a new stake in ProShares Ultra Nasdaq Biotechnology during the 4th quarter worth approximately $424,000. Finally, Palumbo Wealth Management LLC acquired a new stake in ProShares Ultra Nasdaq Biotechnology in the third quarter valued at approximately $766,000.
About ProShares Ultra Nasdaq Biotechnology
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.
Further Reading
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
